ONC Share Price

Open 0.61 Change Price %
High 0.61 1 Day 0.00 0.00
Low 0.56 1 Week -0.02 -3.23
Close 0.60 1 Month 0.04 7.14
Volume 109058 1 Year 0.27 81.82
52 Week High 1.13
52 Week Low 0.19
ONC Important Levels
Resistance 2 0.65
Resistance 1 0.63
Pivot 0.59
Support 1 0.57
Support 2 0.55
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
SC 60.83 -0.44%
BBD-B 2.36 1.29%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
CQE 0.14 16.67%
DNT 0.16 14.29%
CUM 0.90 13.92%
CUM 0.90 13.92%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
AVP 0.04 -20.00%
AVP 0.04 -20.00%
AVP 0.04 -20.00%
AVP 0.04 -20.00%
P 0.08 -11.11%
P 0.08 -11.11%
GEN 0.08 -11.11%
GEN 0.08 -11.11%
CTU-A 0.19 -9.52%
More..

Oncolytics Biotech Inc (TSE: ONC)

ONC Technical Analysis 3
As on 16th Oct 2017 ONC Share Price closed @ 0.60 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.51 & Buy for SHORT-TERM with Stoploss of 0.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
ONC Target for October
1st Target up-side 0.75
2nd Target up-side 0.83
3rd Target up-side 0.92
1st Target down-side 0.51
2nd Target down-side 0.43
3rd Target down-side 0.34
ONC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncolyticsbiotech.com
ONC Address
ONC
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada
Phone: 403-670-7377
Fax: 403-283-0858
ONC Latest News
Interactive Technical Analysis Chart Oncolytics Biotech Inc ( ONC TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oncolytics Biotech Inc
ONC Business Profile
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.